Dendritic cell vaccination for cancer therapy (Q34293614)

1 August 2017

1 reference

title

Dendritic cell vaccination for cancer therapy (English)

1 reference

1 August 2017

1 reference

Nestle FO

1

1 reference

PubMed ID

11426654

1 August 2017

language of work or name

English

0 references

publication date

1 December 2000

1 reference

1 August 2017

1 reference

1 August 2017

19

1 reference

1 August 2017

56

1 reference

1 August 2017

6673-6679

1 reference

https://scigraph.springernature.com/pub.10.1038/sj.onc.1204095

1 August 2017

0 references

cites work

Immunobiology of dendritic cells

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1204095

In breast carcinoma tissue, immature dendritic cells reside within the tumor, whereas mature dendritic cells are located in peritumoral areas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1204095

CD34+ hematopoietic progenitors from human cord blood differentiate along two independent dendritic cell pathways in response to GM-CSF+TNF alpha

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1204095

Plasmacytoid monocytes migrate to inflamed lymph nodes and produce large amounts of type I interferon

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1204095

Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1204095

Dendritic cells in cancer immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1204095

The distinct surface of human blood dendritic cells, as observed after an improved isolation method

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1204095

The enigmatic plasmacytoid T cells develop into dendritic cells with interleukin (IL)-3 and CD40-ligand

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1204095

Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1204095

Identification of proliferating dendritic cell precursors in mouse blood

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1204095

Influence of dendritic cells on tumor growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1204095

Phase I study in melanoma patients of a vaccine with peptide-pulsed dendritic cells generated in vitro from CD34(+) hematopoietic progenitor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1204095

Granulocyte-macrophage colony-stimulating factor promotes differentiation and survival of human peripheral blood dendritic cells in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1204095

Processing of some antigens by the standard proteasome but not by the immunoproteasome results in poor presentation by dendritic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1204095

Induction of antigen-specific cytolytic T cells in situ in human melanoma by immunization with synthetic peptide-pulsed autologous antigen presenting cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1204095

Induction of cytotoxic T cell responses and tumor immunity against unrelated tumors using telomerase reverse transcriptase RNA transfected dendritic cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1204095

Dendritic cells capture killed tumor cells and present their antigens to elicit tumor-specific immune responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1204095

Phase 1 study in patients with metastatic melanoma of immunization with dendritic cells presenting epitopes derived from the melanoma-associated antigens MART-1 and gp100.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1204095

Bone marrow-generated dendritic cells pulsed with a class I-restricted peptide are potent inducers of cytotoxic T lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1204095

Proliferating dendritic cell progenitors in human blood

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1204095

Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor alpha

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1204095

Systemic administration of interleukin 2 enhances the therapeutic efficacy of dendritic cell-based tumor vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1204095

The nature of the principal type 1 interferon-producing cells in human blood

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1204095

Vaccination with mage-3A1 peptide-pulsed mature, monocyte-derived dendritic cells expands specific cytotoxic T cells and induces regression of some metastases in advanced stage IV melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1204095

Dendritic cell vaccines for cancer immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1204095

Therapy of murine tumors with tumor peptide-pulsed dendritic cells: dependence on T cells, B7 costimulation, and T helper cell 1-associated cytokines

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1204095

GM-CSF and TNF-α cooperate in the generation of dendritic Langerhans cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1204095

Dendritic cells as mediators of tumor-induced tolerance in metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1204095

7 January 2021

Vaccination with tumor-antigen-pulsed dendritic cells induces in vivo resistance to a B cell lymphoma.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1204095

7 January 2021

Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1204095

7 January 2021

Monocyte-derived dendritic cells have a phenotype comparable to that of dermal dendritic cells and display ultrastructural granules distinct from Birbeck granules

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1204095

7 January 2021

CD83+ blood dendritic cells as a vaccine for immunotherapy of metastatic renal-cell cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1204095

7 January 2021

Presence of IgE antibodies to bovine serum albumin in a patient developing anaphylaxis after vaccination with human peptide-pulsed dendritic cells

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1204095

7 January 2021

Bone marrow-derived dendritic cells pulsed with synthetic tumour peptides elicit protective and therapeutic antitumour immunity

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1204095

7 January 2021

Infusion of dendritic cells pulsed with HLA-A2-specific prostate-specific membrane antigen peptides: a phase II prostate cancer vaccine trial involving patients with hormone-refractory metastatic disease

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1204095

7 January 2021

Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1204095

7 January 2021

Reciprocal control of T helper cell and dendritic cell differentiation

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1204095

7 January 2021

Novel methods to monitor antigen-specific cytotoxic T-cell responses in cancer immunotherapy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1204095

7 January 2021

Identifiers

DOI

10.1038/SJ.ONC.1204095

1 reference

PubMed ID

11426654

Dimensions Publication ID

1 August 2017

0 references

1 reference

PubMed ID

11426654